{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18","spread":"4.4","upperLimit":"37","value":"26"},{"groupId":"OG001","lowerLimit":"23","spread":"4.5","upperLimit":"41","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"description":"A neurological exam will be completed at baseline and at study week 5 for both strata. An additional exam at week 10 will be done for patients in Stratum 1. Additional exams will be done at any time if the treating oncologist deems it clinically necessary . Neurotoxicity will be scored using a standardized neurological exam form developed for the study that is based on the Modified \"Balis\" Pediatric Scale of Peripheral Neuropathies. Treatment groups will be compared with respect to the proportion experiencing a grade 2 or higher toxicity from the following list of neurologic toxicities captured on the Neurologic Exam Form including sensory neuropathy, motor neuropathy, laryngeal nerve, constipation/neuro-constipation, jaw pain, or other specified abnormalities noted by the attending physician. Percentage of patients with one or more Grade 2 or higher noted neurotoxicity symptoms on any item in the Balis scale will compared between arms.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral glutamic acid 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).","id":"OG000","title":"Arm I Glutamic Acid"},{"description":"Patients receive oral placebo 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).","id":"OG001","title":"Arm II Placebo"}],"paramType":"NUMBER","populationDescription":"Patients reporting baseline and post-baseline observation","reportingStatus":"POSTED","timeFrame":"10 weeks","title":"Neurotoxicity as Measured by a Scored Neurologic Examination at Baseline, 5 Weeks, and 10 Weeks (if Applicable)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}